The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 15, 2019

Filed:

Feb. 01, 2016
Applicant:

The University of Birmingham, Birmingham, GB;

Inventors:

Mark Cobbold, Winchester, MA (US);

David Millar, Winchester, MA (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 47/68 (2017.01); C07K 16/30 (2006.01); A61K 39/12 (2006.01); A61K 39/245 (2006.01); A61K 47/64 (2017.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/245 (2013.01); A61K 47/646 (2017.08); A61K 47/6811 (2017.08); A61K 47/6849 (2017.08); A61K 47/6881 (2017.08); A61K 2039/585 (2013.01); A61K 2039/6056 (2013.01); C12N 2710/16134 (2013.01);
Abstract

A variety of targeting moiety peptide epitope complexes (TPECs) are described in different embodiments. In each of the embodiments, however, a targeting moiety may be used to deliver the TPEC to an area of unwanted cells, allowing for a therapeutic effect to be delivered locally. The TPEC also contains a plurality of T-cell epitopes. The TPEC further comprises cleavage sites that release the T-cell epitopes from the targeting agent, and in some embodiments from each other, when they are in the microenvironment of the unwanted cells. Although the arrangement and number of T-cell epitopes varies in different embodiments described herein, once cleaved from the targeting agent (and any neighboring T-cell epitopes), the T-cell epitopes function by stimulating an immune response against the unwanted cells.


Find Patent Forward Citations

Loading…